

Testing the Addition of an Immunotherapy Drug, Cemiplimab, Before Surgery to Up-front Surgery for Advanced Skin Cancer

NRG
ONCOLOGY

Advancing Research. Improving Lives.™



Visit the patient
webpage for this study:



ABOUT THE TRIAL

NRG-HN014 is a clinical study that will be testing if adding the immunotherapy drug called “Cemiplimab” (REGN2810) prior to surgery can extend the length of time without your cancer returning for people with advanced skin cancer. Typically, patients with this type of cancer are treated with surgery first and, depending the results, may require radiation after surgery. For patients who get the usual approach, about 75 out of 100 are free of cancer after 2 years. Researchers want to know if the approach of surgery with the drug cemiplimab is better, worse, or the same as the usual treatment for people with advanced skin cancer.

ABOUT NRG ONCOLOGY

As one of the five research groups in the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), NRG Oncology carries out clinical trials on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization includes investigators, medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians. The NRG Oncology includes more than 1,300 research sites worldwide, primarily in the United States and Canada. NRG Oncology is a non-profit research organization, funded mainly through grants from the NCI. To contact NRG Oncology, call 267-519-6630 or email info@nrgoncology.org

Frequently Asked Questions

What is a clinical trial?

Clinical trials are research studies that look to find better ways to prevent, diagnose, or treat disease.

Who can join this study?

People with advanced skin cancer that is able to be removed with surgery.

Am I required to be in this study?

No. Taking part in this study is voluntary. You are free to choose to participate or not to participate. If you choose to participate in this study, you are able to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

What are the possible treatments?

If you decide to take part in this study, you will either get the study drug cemiplimab before surgery for your cancer or you will have up-front surgery. If you receive cemiplimab, you will receive it before surgery every 3 weeks for up to 12 weeks. In either case, you may also receive radiation after surgery depending on the tumor tissue results from surgery. If you are treated with cemiplimab before surgery, then tumor tissue results will also determine whether or not you receive cemiplimab, every 6 weeks for up to 24 weeks, after surgery, and radiation if given.

How long will I be in this study?

After you finish your treatment, your doctor and study team will watch you for side effects. They will check you every 3 to 4 months for 2 years after treatment. After that, they will check you every 6 months for 1 year and then annually. This means you will keep seeing your doctor annually after treatment.

Are there side effects?

There may be some. The drug used in this study may affect how different parts of your body work such as your liver, kidneys, heart, and blood. The study doctor will test your blood and let you know if changes occur that may affect your health. There is also a risk that you could have other side effects from the study drug, surgery, or radiation. Your doctor will review all of the potential side effects with you.

MORE INFORMATION

Visit the National Cancer Institute website at <https://www.cancer.gov> for more information about studies or general information about cancer.

You may also call: 1-(800)-4-CANCER (1-800-422-6237).